Response of plasma and tissue endothelin‐1 to liver ischemia and its implication in ischemia‐reperfusion injury

Eisuke Kawamura, Naoki Yamanaka, Eizo Okamoto, Fumihito Tomoda, Kazutaka Furukawa – 1 April 1995 – This study was designed to investigate the changes in plasma and tissue endothelin‐1/endothelin‐2 (ET) after liver ischemia and to assess the protective effect of anti‐ET 1/ET 2 monoclonal antibody (ET antibody) against ischemia‐reperfusion injury. The ET levels in the liver tissue, hepatic venous blood of the ischemic and non‐ischemic sides, and in the portal venous blood were measured before and after partial liver ischemia for 1 hour in the adult dog.

Translocation of different forms of transferrin from blood to bile in the rat

Erwin Regoeczi, Paul A. Chindemi – 1 April 1995 – Five different forms of transferrin (rat apo [iron‐free], rat diferric, diferric rat asialo, human diferric, and diferric human asialotransferrin type 3) were used to monitor the passage of this protein and its metal to the bile. Cumulative biliary excretion of the dose over 3 hours was determined. In addition, an excretion profile was constructed from the concentration of tracer in bile samples collected over 10‐minute intervals.

Effects of pentoxifylline pretreatment on Kupffer cells in rat liver transplantation

Koichi Kozaki, Hiroto Egawa, Luiz Bermudez, Emmet B. Keefe, Samuel K. So, Carlos O. Esquivel – 1 April 1995 – Previous research with pentoxifylline (PTX), a methylxanthine phosphodiesterase inhibitor, suggests that this drug may be capable of suppressing the activation of Kupffer cells and thereby help decrease liver injury after transplantation. To investigate this possibility, the current study sought to determine whether the release of O2− and tumor necrosis factor (TNF) from Kupffer cells in donor livers can be suppressed if the organs are exposed to PTX before preservation.

Proliferation and hypertrophy of liver cells surrounding islet grafts in diabetic recipient rats

Monique E. De Paepe, Bart Keymeulen, Daniel Pipeleers, Günter Klöppel – 1 April 1995 – The liver offers an adequate site for the metabolic function of pancreatic islet implants. Little is known about the effects of the islet grafts on the host organ. This study examines liver tissue of normal or streptozotocin (STZ)‐diabetic rats at different intervals following intraportal injection of syngeneic islets. Implantation of 800‐islet—grafts, containing 0.9 million beta cells, normalized overt diabetes within 14 days.

Simultaneous detection of both hepatitis B virus DNA and hepatitis C virus RNA using a combined one‐step polymerase chain reaction technique

Ke‐Qin Hu, Chang‐Hong Yu, Sunny Lee, Federico G. Villamil, John M. Vierling – 1 April 1995 – Hepatitis C virus (HCV) RNA polymerase chain reaction (PCR) is widely used for diagnosis of HCV infection and evaluation of therapy. The sensitive hepatitis B virus (HBV) DNA PCR is often reserved for detection of quantities of HBV DNA that are insufficient for hybridization. Application of both PCR techniques is limited by their labor‐intensity, potential for contamination, and substantial time required for analysis.

Cellular immune responses in patients with dual infection of hepatitis B and C viruses: Dominant role of hepatitis C virus

Sun‐Lung Tsai, Yun‐Fan Liaw, Chau‐Ting Yeh, Chia‐Ming Chu, George C. Kuo – 1 April 1995 – Several lines of evidence have suggested that immune mechanisms are involved in the pathogenesis of hepatitis B virus (HBV)— and hepatitis C virus (HCV)‐related hepatitis. Study of patients with dual HBV and HCV infection raises the question of which is etiologically more relevant in determining the liver cell damage.

HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis

James A. Underhill, Peter T. Donaldson, Derek G. Doherty, Koji Manabe, Roger Williams – 1 April 1995 – In recent years there has been an increasing interest in the link between susceptibility to autoimmune liver disease and genes of the HLA system, although the role of the DPB1 locus in British patients has only been investigated in autoimmune hepatitis.

Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid

François Durand, Jacques Bernuau, Dominique Pessayre, Didier Samuel, Jacques Belaiche, Claude Degott, Henri Bismuth, Jacques Belghiti, Serge Erlinger, Bernard Rueff, Jean Pierre Benhamou – 1 April 1995 – Isoniazid and pyrazinamide are well‐known hepatotoxic drugs, often used in combination. The aim of this study was to assess the prognostic influence of pyrazinamide on the outcome of fulminant or subfulminant liver failure caused by antituberculous therapy. Eighteen patients with fulminant or subfulminant liver failure due to antituberculous therapy were studied.

Subscribe to